CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. - Wikidata - wikimedia - TriplyDB

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

http://www.wikidata.org/entity/Q37272860

about

Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT score Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology.A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.Proteomic studies associated with Parkinson's disease.Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis.Biomarker Research in Parkinson's Disease Using Metabolite Profiling.Parkinson's Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma.Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?Assessments of plasma ghrelin levels in the early stages of parkinson's disease.Combining clinical and biofluid markers for early Parkinson's disease detection.Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease.Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure

P2860

Q26744782-52E6046D-2E0C-4E22-B38F-D0632F522C4C Q29048624-55094C7A-947D-44A2-8EAE-94C193987AFF Q33698810-5BBA49B2-0FC9-4E26-BA89-9FDF3DCC77CE Q33701172-DE5769FA-075B-4BC5-AB78-5B9000DC3DC1 Q33754677-DBCAB664-E592-4824-B5DD-9E15887BBAF9 Q37629836-245DBB98-12FB-442C-A64D-D8F812ED358B Q38653383-466B0ED2-FA38-4E99-8FBE-BB0D4FC61935 Q38761399-54DBF473-1CF9-413B-933C-7D26B85C0574 Q38761409-EA8C3B91-B163-4814-A3F9-CE4CA8EB7A6F Q38792540-F84E4061-EBF1-4BC7-8B82-E4F1E7399DCD Q38889950-E8F955F0-180D-4520-9978-C8937CDD58A3 Q39010887-7BE00D86-8DC7-4D72-9487-65741EDF3EFF Q39149219-6F3B0DC7-5CDE-4FBC-9DA2-546AD783C718 Q39366291-53D716F0-D29F-4080-9DF2-B52D5A71E989 Q40053985-31BEDE44-1CB6-44AA-9A98-366BFA623872 Q41666702-D94F0327-109A-4D5B-8D5A-71D6ADE04C93 Q41817806-35553964-1670-4ADC-95F8-7BF0F5D6E470 Q45915163-3F8B39CE-9E81-4599-92A2-CACAFC3A3EFD Q46012657-E18E302B-BF2A-4EEC-B372-6DFF1BF45638 Q47587631-C6876FD6-C3D5-4406-8744-BC16D5BC17D8 Q47657093-55D75F44-BED4-45F1-B30D-E5991F5617CA Q47990737-5F5911C0-2841-4DA5-B977-262A82CF418A Q48129130-6B896704-A31A-4515-9DFA-12F33F828514 Q48623727-DCB00C7C-D275-428E-A885-2ECED0A69451 Q49202410-465BDD34-AF0D-48A0-BEE4-5086C95AE5F6 Q50506611-B4BD3642-F358-43DB-ABBB-52B39A46C441 Q51298413-D134729E-FE41-4C36-8009-3E354D7A045B Q58585963-9AAE8BFE-C029-4EA9-81CA-12B1EBB58010 Q58699032-62C4C8D1-A3F2-40F5-9000-4C3A584A068B Q59137487-3AC21B80-1B02-4052-A5EC-02253E9BD36F

P2860

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

http://www.wikidata.org/entity/Q37272860

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CSF biomarkers associated with ...... sion Markers Initiative study.

@en

CSF biomarkers associated with ...... sion Markers Initiative study.

@nl

type

label

CSF biomarkers associated with ...... sion Markers Initiative study.

@en

CSF biomarkers associated with ...... sion Markers Initiative study.

@nl

prefLabel

CSF biomarkers associated with ...... sion Markers Initiative study.

@en

CSF biomarkers associated with ...... sion Markers Initiative study.

@nl

P1433

Q37272860-E356CDF7-27A4-4B95-B191-578DC5E97474

P1476

Q37272860-009CF845-548A-4463-9997-D792D7F11280

P2093

Q37272860-008BDC09-8720-493C-827F-75496B23943F

Q37272860-175A62E4-8FF2-4AA3-9BB6-88EC3A90BACA

Q37272860-1ECD89FB-3C30-4E37-B296-7E6FED965D20

Q37272860-29F2477C-6817-4986-9106-432724E5B679

Q37272860-2C30EC0D-B453-49AE-BBEC-09BF3F237B27

Q37272860-2E099619-A6BB-4E36-AF6F-B400D1106B86

Q37272860-2E5F95DE-98D1-4EE3-A213-9317BA1E814A

Q37272860-30E12D23-B5C6-42F7-AFA7-E8EEBB2A0168

Q37272860-68D2EEBA-4D9D-4E13-A1C1-58CA30006137

Q37272860-75FDBD23-EB43-4195-9E6B-D5555809DDDB

P2860

Q37272860-0BC2E5FD-9CE9-4DE3-B880-D50013A3060C

Q37272860-1CEE557E-CF81-40F9-9C28-2A1ADDF7B219

Q37272860-1FCDD092-9510-4E4D-83AF-5BE17538D405

Q37272860-2233F51F-8B9B-4C3B-9936-78B70CD08B5E

Q37272860-2264856E-9FF3-462A-9AC5-D959F4DEA5FB

Q37272860-28F791CB-53A9-45E0-B7C3-27DA42F4E9D0

Q37272860-3103A1B6-231C-4381-A596-B6BF1FA8299E

Q37272860-386C6E18-76C2-42A6-8992-8127EC07C41D

Q37272860-3B1A5AEE-65E7-4899-80B8-A9AD5CDF12A4

Q37272860-3B670F0E-077B-478E-A481-CE99C2B90F3A

P2888

Q37272860-7E159625-A90D-4D20-B765-CE5C5DB8223C

P304

Q37272860-F1C1080A-1E6F-4138-BA17-360302A1DB77

P31

Q37272860-C3A2914D-3CA4-42B2-B8E4-D86B213EDAFF

P356

Q37272860-68D91F6A-0D57-461C-95FD-6DD833CDAEDD

P433

Q37272860-D0B0B1B4-5124-4EFF-AC36-167198D91F6B

P478

Q37272860-D05E92FC-8FAC-4852-A862-F71158412145

P50

Q37272860-1E8FABE5-E8CE-49C6-9F99-F12B9C1FD602

Q37272860-250028A8-D922-4F2F-8A70-91EFAC4E5237

Q37272860-52B4629D-7F71-4D03-B7B7-2CA4AA238E26

Q37272860-62F85B91-DD98-4830-9186-A6C2D16323DA

Q37272860-A0BF3377-0553-4281-A50E-E73A710E71B6

Q37272860-A324BF30-E3EE-40C8-8960-9425AF22FF39

Q37272860-D0A5D59F-BFAA-4FA4-B266-1D2856587439

Q37272860-D477BDE1-7533-4F34-8CF3-260C2BCAD00E

P577

Q37272860-5F556637-7D5A-46BB-9F46-0F21A2D2CF15

P5875

Q37272860-2B267784-FE55-4A8A-87B0-F73F3862405F

P698

Q37272860-94F9C2E1-5066-4D06-9420-35595D7673AF

P921

Q37272860-54EBD49E-5119-4415-B26A-8F9620F37F0D

Q37272860-783302ED-8C40-4B41-A030-3A8045738D15

P932

Q37272860-0E20D9C3-31B4-45EB-874A-34EF09AB4135

P356

S00401-016-1552-2

P1433

Acta Neuropathologica

P1476

CSF biomarkers associated with ...... sion Markers Initiative study.

@en

P2093

Alice S Chen-Plotkin

http://www.w3.org/2001/XMLSchema#string

Chelsea Caspell-Garcia

http://www.w3.org/2001/XMLSchema#string

Christopher S Coffey

http://www.w3.org/2001/XMLSchema#string

Danna Jennings

http://www.w3.org/2001/XMLSchema#string

David J Irwin

http://www.w3.org/2001/XMLSchema#string

Douglas R Galasko

http://www.w3.org/2001/XMLSchema#string

Ju-Hee Kang

http://www.w3.org/2001/XMLSchema#string

Kenneth Marek

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Mark Frasier

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

Distinct α-synuclein strains differentially promote tau inclusions in neurons

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Neuropathologic substrates of Parkinson disease dementia.

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

P2888

s00401-016-1552-2

P304

935-949

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-016-1552-2

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Brit Mollenhauer

Andrew Singleton

John Q. Trojanowski

Daniel Weintraub

Caroline M Tanner

P577

2016-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299478524

http://www.w3.org/2001/XMLSchema#string

P698

27021906

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5031365

http://www.w3.org/2001/XMLSchema#string